Adenozinski A2B receptor (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Adenozinski A2B receptor" in Serbian language version.

refsWebsite

Global rank Serbian rank

18nih.gov

4^th place

8^th place

12doi.org

2^nd place

4^th place

5archive.today

14^th place

22^nd place

5bentham-direct.org

low place

1archive.org

6^th place

5^th place

archive.org

Beukers MW, Meurs I, Ijzerman AP (2006). „Structure-affinity relationships of adenosine A2B receptor ligands”. Medicinal Research Reviews. 26 (5): 667—98. PMID 16847822. doi:10.1002/med.20069.

archive.today

Volpini R, Costanzi S, Lambertucci C, Vittori S, Cristalli G (2002). „Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists”. Current Pharmaceutical Design. 8 (26): 2285—98. PMID 12369946. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S (2005). „A2B adenosine receptor antagonists: recent developments”. Mini Reviews in Medicinal Chemistry. 5 (12): 1053—60. PMID 16375751. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA (2006). „Ligands for A2B adenosine receptor subtype”. Current Medicinal Chemistry. 13 (28): 3467—82. PMID 17168717. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003). „Medicinal chemistry and pharmacology of A2B adenosine receptors”. Current Topics in Medicinal Chemistry. 3 (4): 427—43. PMID 12570760. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Ham J, Rees DA (2008). „The adenosine a2b receptor: its role in inflammation”. Endocrine, Metabolic & Immune Disorders Drug Targets. 8 (4): 244—54. PMID 19075778. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.

bentham-direct.org

Volpini R, Costanzi S, Lambertucci C, Vittori S, Cristalli G (2002). „Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists”. Current Pharmaceutical Design. 8 (26): 2285—98. PMID 12369946. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S (2005). „A2B adenosine receptor antagonists: recent developments”. Mini Reviews in Medicinal Chemistry. 5 (12): 1053—60. PMID 16375751. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA (2006). „Ligands for A2B adenosine receptor subtype”. Current Medicinal Chemistry. 13 (28): 3467—82. PMID 17168717. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003). „Medicinal chemistry and pharmacology of A2B adenosine receptors”. Current Topics in Medicinal Chemistry. 3 (4): 427—43. PMID 12570760. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Ham J, Rees DA (2008). „The adenosine a2b receptor: its role in inflammation”. Endocrine, Metabolic & Immune Disorders Drug Targets. 8 (4): 244—54. PMID 19075778. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.

doi.org

Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2002). „N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands”. Journal of Medicinal Chemistry. 45 (15): 3271—9. PMID 12109910. doi:10.1021/jm0109762.
Baraldi PG, Tabrizi MA, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid NA, Moorman AR, Varani K, Gessi S, Merighi S, Borea PA (2004). „Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists”. Journal of Medicinal Chemistry. 47 (6): 1434—47. PMID 14998332. doi:10.1021/jm0309654.
Beukers MW, Meurs I, Ijzerman AP (2006). „Structure-affinity relationships of adenosine A2B receptor ligands”. Medicinal Research Reviews. 26 (5): 667—98. PMID 16847822. doi:10.1002/med.20069.
Elzein E, Kalla R, Li X, Perry T, Parkhill E, Palle V, Varkhedkar V, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J (2006). „Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists”. Bioorganic & Medicinal Chemistry Letters. 16 (2): 302—6. PMID 16275090. doi:10.1016/j.bmcl.2005.10.002.
Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B (2006). „Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor”. Journal of Medicinal Chemistry. 49 (1): 282—99. PMID 16392813. doi:10.1021/jm0506221.
Tabrizi MA, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AR, Zaid AN, Varani K, Borea PA (2008). „1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists”. Bioorganic & Medicinal Chemistry. 16 (5): 2419—30. PMID 18077171. doi:10.1016/j.bmc.2007.11.058.
Stefanachi A, Brea JM, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Vidal B, Carotti A (2008). „1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor”. Bioorganic & Medicinal Chemistry. 16 (6): 2852—69. PMID 18226909. doi:10.1016/j.bmc.2008.01.002.
Gao ZG, Jacobson KA (2007). „Emerging adenosine receptor agonists”. Expert Opinion on Emerging Drugs. 12 (3): 479—92. PMID 17874974. doi:10.1517/14728214.12.3.479.
Kolachala V, Ruble B, Vijay-Kumar M, Wang L, Mwangi S, Figler H, Figler R, Srinivasan S, Gewirtz A, Linden J, Merlin D, Sitaraman S (2008). „Blockade of adenosine A2B receptors ameliorates murine colitis”. British Journal of Pharmacology. 155 (1): 127—37. PMC 2440087 . PMID 18536750. doi:10.1038/bjp.2008.227.
Haskó G, Linden J, Cronstein B, Pacher P (2008). „Adenosine receptors: therapeutic aspects for inflammatory and immune diseases”. Nature Reviews. Drug Discovery. 7 (9): 759—70. PMC 2568887 . PMID 18758473. doi:10.1038/nrd2638.
Kim MO, Kim MH, Lee SH, Suh HN, Lee YJ, Lee MY, Han HJ (2009). „5'-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells”. Journal of Cellular Physiology. 219 (3): 752—9. PMID 19194991. doi:10.1002/jcp.21721.
A, Stefanachi; Nicolotti O; Leonetti F (2008). „1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A(2B) adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships”. Bioorganic & medicinal chemistry. 16: 9780. PMID 18938084. doi:10.1016/j.bmc.2008.09.067.

nih.gov

ncbi.nlm.nih.gov

„Entrez Gene: ADORA2B adenosine A2b receptor”.
Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (2002). „N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands”. Journal of Medicinal Chemistry. 45 (15): 3271—9. PMID 12109910. doi:10.1021/jm0109762.
Volpini R, Costanzi S, Lambertucci C, Vittori S, Cristalli G (2002). „Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists”. Current Pharmaceutical Design. 8 (26): 2285—98. PMID 12369946. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Baraldi PG, Tabrizi MA, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid NA, Moorman AR, Varani K, Gessi S, Merighi S, Borea PA (2004). „Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists”. Journal of Medicinal Chemistry. 47 (6): 1434—47. PMID 14998332. doi:10.1021/jm0309654.
Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S (2005). „A2B adenosine receptor antagonists: recent developments”. Mini Reviews in Medicinal Chemistry. 5 (12): 1053—60. PMID 16375751. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA (2006). „Ligands for A2B adenosine receptor subtype”. Current Medicinal Chemistry. 13 (28): 3467—82. PMID 17168717. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Beukers MW, Meurs I, Ijzerman AP (2006). „Structure-affinity relationships of adenosine A2B receptor ligands”. Medicinal Research Reviews. 26 (5): 667—98. PMID 16847822. doi:10.1002/med.20069.
Elzein E, Kalla R, Li X, Perry T, Parkhill E, Palle V, Varkhedkar V, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J (2006). „Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists”. Bioorganic & Medicinal Chemistry Letters. 16 (2): 302—6. PMID 16275090. doi:10.1016/j.bmcl.2005.10.002.
Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B (2006). „Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor”. Journal of Medicinal Chemistry. 49 (1): 282—99. PMID 16392813. doi:10.1021/jm0506221.
Tabrizi MA, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AR, Zaid AN, Varani K, Borea PA (2008). „1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists”. Bioorganic & Medicinal Chemistry. 16 (5): 2419—30. PMID 18077171. doi:10.1016/j.bmc.2007.11.058.
Stefanachi A, Brea JM, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Vidal B, Carotti A (2008). „1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor”. Bioorganic & Medicinal Chemistry. 16 (6): 2852—69. PMID 18226909. doi:10.1016/j.bmc.2008.01.002.
Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003). „Medicinal chemistry and pharmacology of A2B adenosine receptors”. Current Topics in Medicinal Chemistry. 3 (4): 427—43. PMID 12570760. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Gao ZG, Jacobson KA (2007). „Emerging adenosine receptor agonists”. Expert Opinion on Emerging Drugs. 12 (3): 479—92. PMID 17874974. doi:10.1517/14728214.12.3.479.
Kolachala V, Ruble B, Vijay-Kumar M, Wang L, Mwangi S, Figler H, Figler R, Srinivasan S, Gewirtz A, Linden J, Merlin D, Sitaraman S (2008). „Blockade of adenosine A2B receptors ameliorates murine colitis”. British Journal of Pharmacology. 155 (1): 127—37. PMC 2440087 . PMID 18536750. doi:10.1038/bjp.2008.227.
Haskó G, Linden J, Cronstein B, Pacher P (2008). „Adenosine receptors: therapeutic aspects for inflammatory and immune diseases”. Nature Reviews. Drug Discovery. 7 (9): 759—70. PMC 2568887 . PMID 18758473. doi:10.1038/nrd2638.
Ham J, Rees DA (2008). „The adenosine a2b receptor: its role in inflammation”. Endocrine, Metabolic & Immune Disorders Drug Targets. 8 (4): 244—54. PMID 19075778. Архивирано из оригинала 14. 04. 2013. г. Приступљено 20. 09. 2020.
Kim MO, Kim MH, Lee SH, Suh HN, Lee YJ, Lee MY, Han HJ (2009). „5'-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells”. Journal of Cellular Physiology. 219 (3): 752—9. PMID 19194991. doi:10.1002/jcp.21721.
A, Stefanachi; Nicolotti O; Leonetti F (2008). „1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A(2B) adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships”. Bioorganic & medicinal chemistry. 16: 9780. PMID 18938084. doi:10.1016/j.bmc.2008.09.067.